Background-Data on outcomes after catheter ablation of ventricular tachycardia (VT) in patients with nonischemic dilated cardiomyopathy (NIDCM) are insufficient. We aimed to investigate the effects of successful catheter ablation of VT on cardiac mortality in patients with NIDCM. Methods and Results-One hundred two patients with NIDCM (86 men; mean age, 58.8±15.2 years; mean ejection fraction, 33.3±11.9%) underwent VT ablation. After catheter ablation, a programmed ventricular stimulation to test for success was performed. Complete VT noninducibility was achieved in 62 (61%) patients and partial success or failure in 32 (31%) patients. During 2 years of follow-up, VT recurrence was observed in 33 patients (53%) without inducible VTs and in 24 patients (75%) with inducible VT inducible (P=0.041). VT inducibility was associated with higher VT recurrence (adjusted hazard ratio, 1.84; 95% confidence interval, 1.08-3.13; P=0.025). The primary end point of all-cause mortality was reached in 9 patients (15%) with noninducible VTs versus 11 patients (34%) with inducible sustained VTs (P=0.026). VT inducibility was associated with all-cause mortality (adjusted hazard ratio, 2.73; 95% confidence interval, 1.003-7.43; P=0.049). Conclusions-In patients with NIDCM and recurrent sustained VTs, a complete ablation of all inducible VTs may be achieved in 60% of the cases. The complete noninducibility may be a preferable end point of ablation because it was associated with better long-term success. Importantly, if possible to achieve through ablation, a complete VT noninducibility was associated with reduction of the likelihood for all-cause mortality in patients with NIDCM.
T he field of catheter ablation (CA) of ventricular tachycardia (VT) is currently expanding, driven by the advent of new technologies, the growing expertise in this area, and the increasing number of patients with implantable cardioverterdefibrillator (ICD) therapies. In the past decade, there have been an increasing number of studies evaluating different ablation strategies and outcomes after CA of VT in patients with coronary artery disease. [1] [2] [3] [4] [5] [6] However, data on patients with nonischemic dilated cardiomyopathy (NIDCM) are insufficient. In particular, a few publications have suggested rather disappointing long-term outcomes after VT ablation in NIDCM. [7] [8] [9] Another recent study failed to prove any survival benefits after CA of VT in nonischemic heart disease. 10 The reported difference in postablation outcomes between ischemic and nonischemic VTs may be related to certain peculiarities in underlying arrhythmia substrate in NIDCM, such as less late potentials, involvement of epimyocardial layers, and absence of dense scar. 8, [11] [12] [13] The aim of this study was to investigate the effect of VT noninducibility as an end point and proof for successful ablation on the rate of VT recurrence and survival in patients with NIDCM.
Methods

Study Population
In this observational, single-center study, we enrolled patients with sustained VT and NIDCM who underwent CA at the Heart Center of Leipzig between January 2008 and June 2013. Patients with previous VT ablation procedures were not included in the study. In the study were included patients who fulfilled the criteria for dilated cardiomyopathy recommended from the recent guidelines. 14 Ischemic heart disease was previously excluded with coronary angiography. Medical files were carefully reviewed to identify the possible cause of the underlying dilated cardiomyopathy. Patients without any identifiable cause were classified as having idiopathic NIDCM and the rest as secondary NIDCM.
Before the CA procedure, all patients signed an informed consent for undergoing the procedure and for the use of their clinical data for study purposes. The study was approved by the institutional review committee. The patients were prepared according to the clinical routine at our institution. The procedure was performed under conscious sedation. The primary mapping approach was endocardial in all cases. After a single transseptal puncture, a steerable sheath (Agilis; St. Jude Medical) was used to introduce the ablation catheter. All patients were administered heparin intravenously to achieve an activated clothing time of ≥ 300 s. If an epicardial VT was suspected, on the basis of ECG morphology, lack of endocardial low-voltage areas, or incongruous endocardial activation map, a subxiphoid puncture was performed.
In patients without ongoing VT, a programmed ventricular stimulation (PVS) was performed to test for VT inducibility. Signals were recorded using a multichannel recording system (Prucka CardioLab; GE Healthcare, Waukesha, WI). The PVS protocol included stimulation from the right ventricular apex and outflow tract with 4 different basic cycle lengths (500, 430, 370, and 330 ms), and introduction of ≤3 extrastimuli until the ventricular effective refractory period or coupling interval of 200 ms was reached. If the VT was still not inducible, additional stimulation in the left ventricle was performed. The same induction protocol was used to reinduce the VT after CA.
Electroanatomic Mapping and CA
Endocardial left ventricular mapping was performed using electroanatomic 3-dimensional mapping systems (Carto-3 or Carto-RMT; Biosense Webster Inc, CA or EnSite; St. Jude Medical Inc). Electroanatomical voltage mapping was used to delineate the underlying substrate. Local bipolar electrograms, demonstrating a peak-to-peak amplitude of ≥1.5 mV, were defined as healthy and low-amplitude electrograms <0.5 mV were defined as dense scar. In cases of normal left ventricular (LV) electrograms, right ventricular or epicardial mapping was additionally performed. All fragmented and late potentials were annotated on the map. In patients with ongoing or hemodynamically stable VTs, activation and entrainment mapping were performed to localize the exit sites and critical isthmuses of VT. Activation mapping was also performed in cases of frequent uniform premature ventricular beats.
Open-irrigated tip ablation catheters were used to perform radiofrequency ablation. Power settings of ≤50 W and irrigation rates of ≤30 mL/min (Navistar Thermocool or Navistar Thermocool-RMT Biosense Webster Inc) or power settings of ≤50 W and irrigation rates of ≤17 mL/min (Coolflex catheter, St. Jude Medical Inc) were used. During the CA, PVS was performed to reinduce the VTs. Because of the uncertainty to define the clinical VT, we adopted the complete noninducibility as an end point and proof for success of the ablation procedure. For that reason, patients were divided into 2 groups depending on the inducibility: group 1, complete success defined as noninducibility of any VT and group 2, partial success or failure defined as persistent inducibility of sustained VT after CA. 15
Patient Follow-Up
After discharge, all patients were followed up at scheduled outpatient visits every 3 months or earlier in the case of ICD shock therapies. The follow-up was limited to 2 years. Data on VT recurrences and device therapies were collected through device interrogation at these regular visits. Mortality data were confirmed via telephone contact with the referring cardiologists or primary care physicians.
The primary end point of the study was all-cause mortality. The recurrence of sustained VT requiring ICD therapy was defined as a secondary end point.
Statistical Analysis
Continuous variables with normal distribution are reported as mean±SD, whereas categorical variables are reported as absolute numbers and proportions. Student t test, χ 2 test, and Fisher exact test were used to compare differences across groups. Survival free from VT recurrence during the follow-up period was estimated by the Kaplan-Meier method, and log-rank statistics were used to compare different groups. Multivariable Cox regression analysis using the method of forced entry in which all variables were forced into the model simultaneously was used to identify correlates of VT recurrence and all-cause mortality. In the model were included variables with P≤0.100 based on the univariate significance. All tests were 2-sided, and P values of <0.05 were considered statistically significant. The statistical analysis was performed using SPSS 17.0 (IBM, Armonk, NY).
Results
Baseline Clinical Characteristics
One hundred two consecutive patients (86 men; mean age, 58.8±15.2 years; mean ejection fraction, 33.3±11.9%) with primary and secondary NIDCM and sustained VTs were included in the study. Thirty-five patients (34%) were referred for ablation because of electrical storms; 57 patients (56%) had at least 1 ICD shock in the preceding 6 months; and 12 patients (12%) presented with an incessant VT. Fifty-five patients (54%) were on antiarrhythmic drugs at the time of admission. Fifty-nine (58%) patients had secondary NIDCM, and the cause remained unclear in the rest 43 (42%). The causes of NIDCM and the other baseline clinical characteristics and comorbidities are presented in Table 1 .
Baseline Procedural Characteristics and VT Inducibility Before Ablation
Endocardial electroanatomic mapping (voltage, activation, or both) was the primary mapping approach and was performed in all 102 patients. Voltage mapping was performed in 87 patients. Low-voltage (0.5-1.5 mV) endocardial areas were observed in 48 (46%) patients; both endocardial and epicardial low-voltage areas (0.5-1.5 mV) were observed in 25 (24%) patients. In 17 (16%) patients, low-voltage areas (0.5-1.5 mV) were observed only on the epicardial LV surface. The mean endocardial bipolar voltage area (0.5-1.5 mV) was 34.6±36.2 cm 2 , and the mean epicardial bipolar voltage area (0.5-1.5 mV) was 58±58.4 cm 2 . The mean unipolar voltage area (< 8.3 mV) endocardially was 118±73 cm 2 . In 15 (14%) patients, only activation mapping of ongoing VT or presumed premature ventricular beat as triggers of VT was performed.
WHAT IS KNOWN
• Previous studies have reported a reduction of ventricular arrhythmia burden after successful catheter ablation in nonischemic dilated cardiomyopathy.
• Whether a reduction in arrhythmias after catheter ablation is associated with improved survival has not been clear.
WHAT THE STUDY ADDS
• In this series of patients with nonischemic dilated cardiomyopathy undergoing catheter ablation, achievement of noninducibility for any ventricular tachycardia was associated with a decrease in all-cause mortality.
• A reduction of ventricular tachycardia recurrence rate was also associated with improved survival. VT was ongoing at the start of the procedure in 12 patients (12%), was inducible with PVS in 73 patients (72%), and remained noninducible in 13 patients (13%). PVS at the beginning of the procedure was not performed in 4 (4%) cases, and ongoing VTs or frequent premature ventricular beat were targeted instead. A mean of 2.1±1.3 VTs per patient were inducible. The baseline procedural characteristics are presented in Table 2 .
Acute Outcomes and Procedure-Related Complications
On the basis of the inducibility after ablation, a complete success was observed in 62 (61%) patients; partial success or failure was observed in 32 (31%) patients. PVS after ablation was not performed in 8 (8%) cases because of the fact that only the ongoing VT and premature ventricular beat were targeted in 7 patients and because pericardial tamponade occurred in 1 case. Overall 9 (9%) patients experienced postprocedural complications ( Table 2 ).
Causes of Death
All patients except 2 died from cardiac arrest, worsening of heart failure or combination of both so that cardiac mortality contributed almost entirely to the mortality in this cohort of patients without coronary artery disease. One patient died from tension pneumomediastinum as a consequence of surgical drainage of pericardial tamponade after cardiac resynchronization implantation and another one from unrecognized hypoglycemia ( Table 3 ).
Effects of Postablation Noninducibility on the VT Recurrence and Correlates for VT Recurrence
Because of the omitted PVS after CA in 8 patients, they were excluded from the analysis of the VT recurrence and mortality, given the uncertainty in classifying them as success or failure. The baseline clinical and procedural characteristics of the remaining 94 patients with inducible and noninducible VTs are presented in Table 4 . In comparison with the patients with noninducible VTs, the patients with persistent VT inducibility had more VTs per patient: 2.84±1.46 versus 1.79±1.1; P=0.0001; longer procedure duration: 142±66.9 versus 105±73 minutes; P=0.001; and required more frequently epicardial ablation: 44% versus 21%; P=0.030. Notably, patients with persistently inducible VTs had more procedure-related complications when compared with patients with complete VT noninducibility: 2 (3%) versus 5 (16%); P=0.043.
In 94 patients, after 2 years of follow-up, VT recurrence was observed in 33 patients (53%) with complete success (no VT inducible) and in 24 patients (75%) with partial procedural success or failure (VT inducible; P=0.041). In a univariable analysis, the probability of VT recurrence was significantly higher in the group with inducible VTs when compared with the group without inducible VTs (hazard ratio [HR], 2.01; 95% confidence interval [CI], 1.19-3.41; P=0.01; Figure 1 ). After adjustments for the baseline differences and relevant clinical confounders, such as age, LV ejection fraction, New York Heart Association class, number of VTs per patient, epicardial ablation, eGFR, and use of antiarrhythmic drugs or β-blockers, the persistent inducibility of VT at the end of the procedure and the eGFR were the only significant correlates for VT recurrence (HR for VT inducibility, 1.84; 95% CI, 1.08-3.13; P=0.025 and HR for eGFR, 0.99; 95% CI, 0.977-0.998; P=0.021; Table 5 ).
Effects of Postablation VT Noninducibility on All-Cause Mortality
At the end of the 2-year follow-up period, the primary end point of all-cause mortality was reached in 9 patients (14%) with noninducible VTs versus 11 patients (34%) with inducible sustained VTs at the end of the procedure (P=0.026). In unadjusted analysis, the rate of all-cause death was significantly higher in patients with inducible VTs (HR, 3.08; 95% Figure 2 ). After adjustments for the significant clinical variables (age, atrial fibrillation, chronic pulmonary disease, eGFR, New York Heart Association class, ejection fraction, and time to VT recurrence), the inducibility of any sustained VT at the end of the procedure was significantly associated with all-cause mortality (HR, 2.73; 95% CI, 1.003-7.43; P=0.049). In addition, eGFR (HR, 0.96; 95% CI, 0.93-0.99; P=0.005) and time to VT recurrence (HR, 0.996; 95% CI, 0.992-1.00; P=0.049) were associated with an increased rate of all-cause death ( Table 6 ). Ongoing at start, n (%) 12 (12) Noninducible with PVS at start, n (%) 13 (13) PVS not performed at beginning, n (%) 4 (4)
Remote magnetic navigation, n (%) 7 (7) No. 
Effects of Preablation and Postablation VT Noninducibility on VT Recurrence and All-Cause Mortality
VT recurrence was observed in 8 (62%) of 13 patients with noninducible VTs at the beginning of the procedure versus 26 (51%) of 51 patients rendered noninducible at the end of the ablation (P=0.548). About the all-cause mortality, death occurred in 3 (23%) of 13 primary noninducible patients versus 7 (14%) of 51 patients rendered noninducible after ablation (P=0.411).
Discussion
PVS is a widely accepted tool to test for acute procedural success after CA of VT. [16] [17] [18] Previous studies have shown that VT noninducibility after CA was associated with improved VTfree survival and reduced mortality in patients with coronary artery disease. 2, 5, 18 In contrast, the influence of postprocedural VT inducibility as a proof of acute success on the outcomes in patients with NIDCM is controversial and based on data from several studies with a limited number of patients. 10, 19 
End Points Definition and Acute Outcomes After Ablation
Having in mind the uncertainties in the classification of a VT as a clinical one, as well as some recently published data, we adopted the complete noninducibility of any sustained monomorphic VT as an end point and a proof of acute success after CA. 19 Using this definition, the achieved acute success rate in our study was 60% which is comparable with previously published data. 9, 10 
VT Noninducibility After CA and VT Recurrence
In patients with NIDCM, it was previously demonstrated that inducibility of VT or fibrillation was associated with an increased likelihood of subsequent ICD therapies in addition to 20 In line with this finding, we proved a decreased likelihood of VT recurrence in patients with NIDCM and complete VT noninducibility in comparison with patients with partial success or failure after CA. Previously, Piers et al 19 reached the same conclusion and suggested that noninducibility may be an appropriate end point in patients with NIDCM. In contrast with our results and the data from the above mentioned studies, Tokuda et al 10 could not prove any association between the postablation inducibility and the VT recurrence in a cohort of patients with miscellaneous nonischemic cardiomyopathies, including hypertrophic cardiomyopathy. These contradictory results can be explained by non-re-entrant arrhythmia mechanisms operative in some cardiomyopathies and by differences between the PVS protocols and end point definitions.
VT Noninducibility After CA and Mortality
In this study, we proved for the first time that, if possible to achieve with CA, the complete VT noninducibility was associated with survival benefit in patients with NIDCM. The persistent VT inducibility was associated with an increased likelihood of death. Because in our study most of the patients with NIDCM treated by CA died because of cardiac arrest, worsening heart failure, or a combination of both, a successful CA may have improved the survival chances of these patients, provided a complete noninducibility would have been achieved. At the same time, patients with partially successful ablation or failure experienced less procedure-related complications when compared with those with completely successful procedure. Therefore, the risks of VT recurrences should be weighted carefully against the risks of a prolonged CA. In addition to noninducibility, the time to first VT recurrence was associated with increased mortality. The unfavorable prognosis of patients with earlier VT recurrence may indicate more advanced stage of ventricular remodeling and hence poorer survival or may be the immediate cause of death in some cases. Furthermore, other factors, such as the reduction of the VT burden, may possibly play a role for the decline of the mortality after successful ablation.
On the other hand, an impossibility to achieve a complete acute success may be considered as an indirect evidence of extensive and severe LV scar involvement which by its nature is associated with VT recurrences, loss of contractile function, and as a consequence, with a higher mortality. This hypothesis is supported by a recent study in patients with NIDCM showing that the scar transmurality in late gadolinium enhancement-MRI images of the LV was associated with VT inducibility with PVS. 21
Implications for the Clinical Practice and Future Studies
Our results suggest that, where possible, a modification of the existing substrate to achieve a complete VT noninducibility should be attempted because it may reduce the likelihood of VT recurrence and further deterioration of heart failure in patients with NIDCM. Moreover, the impossibility to achieve a complete elimination of all inducible VTs was associated with increased probability of cardiac and all-cause mortality. This association may be explained with insufficient ablation or severe LV impairment as a consequence of extensive scarring. Further studies are needed to explore the effect of the arrhythmogenic substrate on the mortality in patients with NIDCM.
Study Limitations
Our study was a prospective, observational, single-center study. The presented results are from an experienced center, and patients with previous unsuccessful ablation were excluded; therefore, these data may be not valid for the general population. Another major limitation of defining noninducibility as ablation success is that in some cases, VT remained noninducible at the beginning of the procedure. However, the noninducibility before CA was not significantly different between patients with complete procedural success and partial procedural success or failure. Moreover, patients with noninducible VTs at the start that remained noninducible throughout the entire procedure had similar VT recurrence and mortality outcomes to those that were inducible at the beginning and rendered noninducible after ablation. The possibility that these patients would have done better if ablation was stopped at an earlier end point cannot be excluded. Another limitation is that non-re-entrant mechanisms may influence the inducibility with PVS although re-entry is expected to be the prevailing arrhythmia mechanism in scar-related VTs. Epicardial mapping and ablation were performed only in the half of the patients with persistently inducible VTs, which may possibly influence the acute and long-term outcomes.
Conclusions
In patients with NIDCM and recurrent sustained VTs, a complete ablation of all inducible VTs may be achieved in 60% of the cases. The complete noninducibility may be a preferable end point of ablation because it was associated with better long-term success. Importantly, if possible to achieve through ablation, a complete VT noninducibility was associated with reduction of the likelihood for cardiac and all-cause mortality in patients with NIDCM.
